An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients

John B. Alexis, Antonio E. Martinez, Jose Lutzky

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

In order to determine whether imatinib mesylate (Gleevec), a tyrosine kinase inhibitor that binds the CD-117 (c-kit) receptor, may be of value in the treatment of malignant melanoma, an immunohistochemical analysis of 40 cases of primary and metastatic melanoma was undertaken. Thirty-five of the 40 cases showed 1+ or stronger labelling for CD-117 (up to a maximum of 4+). Three patients with neoplasms showing 4+ staining were selected for imatinib therapy. None responded, c-kit (CD-117) expression in melanoma appears to be common; however, the value of imatinib therapy remains to be proven.

Original languageEnglish (US)
Pages (from-to)283-285
Number of pages3
JournalMelanoma Research
Volume15
Issue number4
DOIs
StatePublished - Aug 2005

Keywords

  • c-kit
  • Chemotherapy
  • Immunohistochemistry
  • Melanoma

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Fingerprint

Dive into the research topics of 'An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients'. Together they form a unique fingerprint.

Cite this